- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- The ReproPsych Group
- CAS Newsletter
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
2013 FACE meeting
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting .
- Read more in our News Archive
Current Studies at Motherisk
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
JAMA 271: 767-770, 1994.
Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner A, Gladstone R, Ashby P, Weksberg R, Einarson T, Koren G: Neurodevelopment of children exposed in utero to carbamazepine monotherapy.
Am J Hum Genet 68: 18-24, 1997.
Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G: Dysmorphology in children exposed in utero to phenytoin and carbamazepine monotherapy; Independent effects of epilepsy and medications.
Koren G: In utero exposure to phenytoin or carbamazepine. Can Fam Physicians 41: 1862-1863, 1995.
JAMA. 1994;272(11):851. doi:10.1001/jama.1994.03520110028019
Koren G: Neurodevelopment after in utero exposure to phenytoin and carbamazepine. JAMA 272: 850-851, 1994.